Island Pharmaceuticals Limited

ILA

AU0000138869

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 01:02:32 13/03/26 pm AEDT			5-day change	1st Jan Change
0.4500 ^AUD	-5.26%		+7.14%	+4.65%

09/03	Island Pharmaceuticals Begins Strategic Collaboration With Australian Infectious Disease Research Organization	MT
04/03	Daily Special: Island Pharmaceuticals, GenusPlus Group, Horizon Gold	FI

Island Pharmaceuticals Admits It Was Not Strictly in Compliance With ASX Listing Rules

Published on 02/10/2026 at 03:30 pm AEDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Island Pharmaceuticals Limited

09/03	Island Pharmaceuticals Begins Strategic Collaboration With Australian Infectious Disease Research Organization	MT
04/03	Daily Special: Island Pharmaceuticals, GenusPlus Group, Horizon Gold	FI
04/03	Island Pharmaceuticals Enters Agreement to Advance Galidesivir Approval, Shares Up 19%	MT
02/03	Island Pharmaceuticals seeks trading halt	RE
25/02	Island Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
10/02	Island Pharmaceuticals Admits It Was Not Strictly in Compliance With ASX Listing Rules	MT
04/02	Island Pharmaceuticals reports placement of A$9 million at A$0.35 each	RE
04/02	Island Pharmaceuticals Says US FDA Confirms Animal Model as Development Pathway for Antiviral Drug Candidate; Shares Rise 10%	MT
04/02	Island Pharmaceuticals to Raise AU$9 Million via Placement	MT
02/02	Island Pharmaceuticals seeks trading halt	RE
07/01	Island Pharmaceuticals says US patent granted for galidesivir in Filoviridae viruses	RE
07/01	Island Pharmaceuticals Secures US Patent for Antiviral Drug Candidate; Shares Rise 12%	MT
05/01	Island Pharmaceuticals says FDA advises it requires additional time to finalise response to co's submission	RE
05/01	Island Pharmaceuticals Says US FDA Needs More Time to Review Galidesivir Submission	MT
17/12	Island Pharmaceuticals Enters Master Service Agreement With Texas Biomedical to Advance Development of Antiviral Molecule	MT

Chart Island Pharmaceuticals Limited

Duration

Period

ILA: Dynamic Chart

Island Pharmaceuticals Ltd is an Australia-based drug repurposing company. The Company is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company